At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 21 enrolled
Drug / intervention
23.4% Hypertonic salinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Center Clinical Trial to Evaluate the Effect of Sclerotherapy on Fistulas and Sinus Tracts in Adult Patients With Hidradenitis Suppurativa
In Brief
A Phase 2 clinical trial evaluating 23.4% Hypertonic saline for Hidradenitis Suppurativa. Completed, enrolled 21 participants across 1 site.
Detailed Summary
This study evaluates the effect of hypertonic saline 23.4% injection in fistulas or sinus tracts in adult patients with hidradenitis suppurativa.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHidradenitis Suppurativa
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJun 2016
Enrollment StartAug 2016
Primary CompletionNov 2022
TodayJul 2026
First PostedJun 20, 2016
Enrollment StartAug 1, 2016
Primary CompletionNov 1, 2022
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 10.0 years ago
Interventions
23.4% Hypertonic salinedrug
Saline Injections